feedback

Accredited by

American Medical Association

Course Description

Only 1 class of glucose-lowering agents—sodium-glucose cotransporter 2 (SGLT2) inhibitors—has been reported to decrease the risk of cardiovascular events primarily by reducing the risk of the development or progression of heart failure. In a landmark trial called Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes [EMPA-REG Outcomes], long-term treatment with empagliflozin prevented fatal and nonfatal heart failure events but did not reduce the risk of myocardial infarction or stroke in diabetic patients.

Activity Details

Credit Types:CME
Credit Amount:1.00 Credits
Release Date:2017-Sep-20
Expiration Date:2020-Sep-20
Estimated Time for Completion:1 hour
Registration Required:Yes
Cost:$30.00

Suggest a CME Activity

[x]

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

[x]

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Send Email to a Colleague

[x]

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.
  • Terms of Use
  • Copyright 2009-2018 OpenCME. All rights reserved.